MALIGNANT HEMANGIOENDOTHELIOMA |
| |
| Authors: | HAZUKI IHDA M.D. YOSHIKI TOKURA M.D. MISAO FUSHIMI M.D. RYUICHI YOKOTE M.D. HIDEO HASHIZUME M.D. SHIGEHO SHIRAHAMA M.D. KEIJI IWATSUKI M.D. KYOKO MURAKAMI M.D. MASAHIRO TAKIGAWA M.D. |
| |
| Affiliation: | Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, Japan, the Department of Dermatology, Fukushima Medical College, Fukushima, Japan, and the Section of Dermatology, Yaizu City Hospital, Yaizu, Japan. |
| |
| Abstract: | ![]()
Background. The administration of interleukin-2 (il-2 ) has recently been reported to be favorable for treating malignant hemangioendothelioma (mhe ). Methods. Two patients with mhe responded well to intra-lesional injections of recombinant il-2 (ril-2 ) without major side effects. The purpose of this study was to characterize cells infiltrating the regressing tumor following ril-2 treatment. Immunohistochemical studies were performed on biopsy specimens taken from ril-2 -injected lesional skin. Results. It was shown that CD8+ lymphocytes and CD56+ natural killer (nk ) cells infiltrated at the ril-2 -injection sites, suggesting that these cells contributed to the tumor regression. In addition, MHE cells bore intercellular adhesion mole-cule-1 (icam -1) whose expression was augmented by rn-2 injections. Conclusions. These findings suggested, that ril-2 not only induces lymphokine-activated killer (lak ) cells and nk cells, but also facilitates these cytotoxic cells to adhere to MHE cells by enhancing icam -1 expression of tumor cells. |
| |
| Keywords: | |
|
|
